HRAS and carcinoma: One patient with an HRAS-mutated thyroid neuro-endocrine tumor received tipifarnib, two patients with a BRCA1-mutated ovarian or cholangiocarcinoma received niraparib or olaparib, one patient with a gastric adenocarcinoma received abemaciclib because of a CDK4 amplification, and one patient with a KRAS G12C-mutated carcinoma of unknown primary received sotorasib.